# US 11,988,679 B2 · Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,988,679 B2
- Document ID: US11988679B2
- Status: Granted
- Kind: B2
- Application number: 17/568,392
- Filed: 2022-01-04
- Published: 2022-05-05
- Granted: 2024-05-21
- Earliest claimed: 2014-09-11
- Assignees: LipoScience, Inc.
- Applicants: LipoScience, Inc.
- Inventors: James D. Otvos; Irina Y. Shalaurova
- Web page: https://patentgrep.com/patent/US11988679B2

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N 2800/32: Cardiovascular disorders
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.

## Claims

### Claim 1

A method of determining a risk parameter for cardiovascular disease (CVD) or events, comprising:
providing a Nuclear Magnetic Resonance (NMR) spectrum of an in vitro biosample comprising blood, plasma, or serum from a subject;
obtaining measurements of HDL particles and inflammatory biomarker GlycA in the biosample;
determining NMR-derived concentrations for an HDL particle size subclass and GlycA, based on the measurements;
programmatically calculating a risk parameter value ((HxI)CVD) of the subject using the NMR-derived concentrations for the HDL particle size subclass and GlycA; and
determining the subject's risk of having and/or developing CVD based, at least in part, on the (HxI)CVD risk parameter value.

### Claim 2 (depends on 1)

The method of claim 1, wherein concentrations are determined for HDL particle size subclasses cH1-cH8.

### Claim 3 (depends on 1)

The method of claim 1, wherein the determining step and/or the calculating step is carried out using a processor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the HDL particle size subclass comprises at least one of the following:
(i) cH1 having a diameter in the range of 7.0-7.6 nm;
(ii) cH8 having a diameter in the range of 11.5-13.5 nm.

### Claim 5 (depends on 4)

The method of claim 4, wherein (HxI)CVD is:
(
H
×
I
)
CVD
=
c
1
⁡
(
cH
⁢
⁢
1
)
+
c
2
⁡
(
INFLAM
)
+
c
3
⁡
(
INTER
H
⁢
1
)
;
or
⁢
(
H
×
I
)
CVD
=
c
4
⁡
(
cH
⁢
⁢
8
)
+
c
5
⁡
(
INFLAM
)
+
c
6
⁡
(
INTER
H
⁢
⁢
8
)
wherein INFLAM is the concentration of GlycA, INTERH1=INFLAM*cH1, INTERH8=INFLAM*cH8, and wherein “c1-c6” represent coefficients from a mathematical model of CVD events in a study population for the associated risk parameter.

### Claim 6 (depends on 5)

The method of claim 5, wherein the (HxI)CVD risk parameter is gender-specific.

### Claim 7 (depends on 6)

The method of claim 6, wherein utilizing the concentration of HDL particle size subclass cH1 provides a male-specific HDL-inflammation multimarker.

### Claim 8 (depends on 6)

The method of claim 6, wherein utilizing the concentration of HDL particle size subclass cH8 provides a female-specific HDL-inflammation multimarker.

### Claim 9 (depends on 1)

The method of claim 1, further comprising electronically providing the calculated (HxI)CVD risk parameter value to a medical professional and/or patient report.

### Claim 10 (depends on 9)

The method of claim 9, further comprising prescribing, recommending, or deciding upon a treatment for the subject based at least in part on the calculated (HxI)CVD risk parameter value.

### Claim 11 (depends on 1)

The method of claim 1, wherein the determining NMR-derived concentrations further comprises deconvolving a composite NMR spectrum of a fitting region of the biosample using a defined deconvolution model with at least eight HDL particle size subclasses.

### Claim 12 (depends on 1)

The method of claim 1, wherein the risk parameter includes an interaction parameter defined by GlycA concentration multiplied by a HDL particle size subclass concentration, wherein the HDL particle size subclass demonstrates gender specificity for CVD events in a study population for the associated risk parameter.

### Claim 13

A system for determining a risk parameter for cardiovascular disease or events, comprising:
a Nuclear Magnetic Resonance (NMR) spectrometer configured to acquire an NMR signal of an in vitro biosample comprising blood, plasma, or serum from a subject; and
a processor in communication with the NMR spectrometer, the processor configured to:
determine NMR-derived concentrations from the NMR signal for an HDL particle size subclass and inflammatory biomarker GlycA; and
programmatically calculate a risk parameter ((HxI)CVD) of the subject using the concentrations for the HDL particle size subclass and inflammatory biomarker GlycA.

### Claim 14 (depends on 13)

The system of claim 13, wherein the processor is further configured to deconvolve a composite NMR spectrum of a fitting region of the NMR signal of the biosample using a defined deconvolution model with at least eight HDL particle size subclasses.

### Claim 15 (depends on 13)

The system of claim 13, wherein the processor is configured to determine concentrations for HDL particle size subclasses cH1-cH8.

### Claim 16 (depends on 13)

The system of claim 13, wherein the processor is configured to determine concentrations for at least one of the following:
(i) cH1 having a diameter in the range of 7.0-7.6 nm;
(ii) cH8 having a diameter in the range of 11.5-13.5 nm.

### Claim 17 (depends on 13)

The system of claim 13, wherein the system is configured to calculate an (HxI)CVD risk parameter and/or monitor the (HxI)CVD risk parameter as a therapeutic target for either (a) raising or lowering a concentration of HDL particles (HDL-P) or (b) lowering inflammation, or both (a) and (b).

### Claim 18 (depends on 13)

The system of claim 13, wherein the system is configured to calculate a measurement of GlycA multiplied by a concentration of a defined subpopulation of HDL particles (HDL-P).

### Claim 19 (depends on 13)

The system of claim 13, wherein the processor is configured to:
(i) determine NMR-derived concentrations of at least eight subpopulations of high density lipoprotein particle (HDL-P) size subclasses in the biosample, and
(ii) calculate a (HxI)CVD risk parameter using:
a defined subset of the determined NMR-derived concentrations, and
at least one interaction parameter comprising the product of a concentration of a defined HDL particle size subclass with a concentration of inflammation biomarker GlycA.

### Claim 20 (depends on 19)

The system of claim 19, wherein the defined HDL particle size subclass demonstrates gender specificity for CVD events in a study population for the associated risk parameter.

### Claim 21

A computer program product for determining a risk parameter for cardiovascular disease or events, the computer program product comprising:
a non-transitory computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
computer readable program code that obtains NMR-derived measurements for at least eight subclasses of HDL-P in a blood, plasma, or serum sample and inflammatory biomarker GlycA;
computer readable program code that determines concentrations of HDL particle size subclasses and/or inflammatory biomarker GlycA using the NMR-derived measurements; and
computer readable program code that calculates a risk parameter ((HxI)CVD) comprising at least one interaction parameter.

### Claim 22 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for deconvolving a composite NMR spectrum of a fitting region of the subject, wherein the computer readable program code deconvolves the composite NMR spectrum using a defined deconvolution model with the at least eight HDL-P subclasses.

### Claim 23 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code that determines concentrations for HDL particle size subclasses cH1-cH8.

### Claim 24 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for determining concentrations for at least one of the following individual HDL particle sizes:
(i) cH1 having a diameter in the range of 7.0-7.6 nm;
(ii) cH8 having a diameter in the range of 11.5-13.5 nm.

### Claim 25 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for calculating (HxI)CVD according to one of the following equations:
(
HxI
)
CVD
=
c
1
(
cH
⁢
1
)
+
c
2
(
INFLAM
)
+
c
3
(
INTER
H
⁢
1
)
;
or
(
HxI
)
CVD
=
c
4
(
cH
⁢
8
)
+
c
5
(
INFLAM
)
+
c
6
(
INTER
H
⁢
8
)
wherein INFLAM is the concentration of inflammatory biomarker GlycA, INTERH1=INFLAM*cH1, INTERH8=INFLAM*cH8, and wherein “c1-c6” represent coefficients from a mathematical model of CVD events in a study population for the associated risk parameter.

### Claim 26 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for determining the concentration of HDL particle size subclass cH1, having an average diameter in the range of 7.0-7.6 nm, to generate (HxI)CVD, to provide a male-specific HDL-inflammation multimarker.

### Claim 27 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for determining the concentration of HDL particle size subclass cH8, having an average diameter in the range of 11.5-13.5 nm, to generate (HxI)CVD, to provide a female-specific HDL-inflammation multimarker.

### Claim 28 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for electronically providing the calculated (HxI) CVD to a medical professional and/or patient report.

### Claim 29 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for prescribing or recommending a treatment for the subject based at least in part on the calculated (HxI) CVD risk parameter value.

### Claim 30 (depends on 21)

The computer program product of claim 21, wherein the non-transitory computer readable storage medium further comprises computer readable program code for programmatically calculating at least one interaction parameter defined by GlycA concentration multiplied by concentration for least one HDL-P subclass concentration, wherein the at least one HDL particle size subclass demonstrates gender specificity for CVD events in a study population for the associated risk parameter.
